Dr McLachlan and Dr Dumas both went on maternity leave and we have appointed two new fellows in their place, Dr Cecilia Orbegoso and Dr Clare Pate.
Over the last few months the team have been testing samples for a specific mutation that has the potential to identify which women will benefit from a novel, targeted drug. We are really pleased with the initial results.
Two years on from the launch of the Gynaecological Cancer Fund we are incredibly pleased to report that three review articles have been published in peer-reviewed journals involving the team that you so generously support. It is thanks to your hard work and the funding of research fellows that this research has been carried out and published.
In the past six months, Dr Banerjee has appointed Dr Lucy Dumas and Dr Jenny McLachlan to join her team and together they are pursuing developments and advancing research across the full range of gynaecological cancers. The ground-breaking projects outlined here would not be possible without the support of the donors and the inspirational fundraisers and volunteers of the Gynaecological Cancer Fund.
Dr Jennifer McLachlan, an advanced oncology trainee from Sydney, joined Dr Banerjee’s team in autumn 2015. She previously worked with Dr Banerjee as a junior doctor and is passionate about gynaecological cancers.
One year on from the launch of the Gynaecological Cancer Fund’s tremendous fundraising, Dr Banerjee reports significant steps towards her goals, including appointing her first dedicated team member, Dr Michele Moschetta.
WHAT’S NEW IN OVARIAN CANCER RESEARCH AND TREATMENT?
6 January 2015
Scientists continue to study the genes responsible for familial ovarian cancer. This research is beginning to yield clues about how these genes normally work and how disrupting their action can lead to cancer. This information eventually is expected to lead to new drugs for preventing and treating familial ovarian cancer.
On behalf of the team at The Royal Marsden Hospital, thank you for your immense support and generous funding for research into gynaecological cancers. I am delighted to let you know that the initial funding target has been achieved to start my team’s research programme which aims at delivering more individualised, precision cancer therapy to women. This would not be possible without your donations.